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Abstract
Background: Early detection of response to treatment is critically important in gastrointes-
tinal stromal tumors (GIST). Therefore, the present systematic review and meta-analysis
assessed the value of 18f-ﬂuorodeoxyglucose positron emission tomography (18FDG–
PET) on prediction of therapeutic response of GIST patients to systemic treatments.
Methods: The literature search was conducted using PubMed, SCOPUS, Cochrane, and
Google Scholar databases, and review article references. Eligible articles were deﬁned as
studies included conﬁrmed GIST patients who underwent 18FDG–PET as well as assessing
the screening role of it.
Results: Finally, 21 relevant articles were included. The analysis showed the pooled sensi-
tivity and speciﬁcity of 18FDG–PET in evaluation of response to treatment of GIST patient
were 0.90 (95%CI: 0.85–0.94; I2 = 52.59,P= 0.001) and 0.62 (95%CI: 0.49–0.75; I2 = 69.7,
P= 0.001), respectively. In addition, the pooled prognostic odds ratio of 18FDG–PET for was
14.99 (95% CI, 6.42–34.99; I2 = 100.0, P< 0.001). The Meta regression showed that sensi-
tivity of 18FDG-PET was higher if the sample size of study was equal or more than 30 cases
(sensitivity = 0.93; 95% CI: 0.89–0.97), when using PET/CT (sensitivity = 0.92; 95% CI:
0.89–0.97), and self-design criteria (sensitivity = 0.93; 95% CI: 0.87–1.0).
Conclusion: The present meta-analysis showed 18FDG–PET has a signiﬁcant value in
predicting treatment response in GIST patients.
Introduction
Gastrointestinal stromal tumors (GIST) are the most common mes-
enchymal tumors that originate from the gastrointestinal tract.1
GISTs are often completely considered resistant to chemotherapy
and are insensitive to irradiation.2–4 The lack of therapeutic agents
and its metastatic nature made a generally poor prognosis in pa-
tients with GISTs.5–7 So, the accurate and early objective assess-
ment of tumor response to treatment has a major important role
in GIST patients.8,9 After introducing of tyrosine kinase inhibitors
such as Imatinib in 2001 for treatment of GISTs, monitoring of
therapeutic response has posed a challenge in these tumors that of-
ten progress slowly.10,11
Current evidence showed the 18F-ﬂuorodeoxyglucose positron
emission tomography (18FDG–PET) is a sensitive tool for evaluat-
ing tumor response in GISTs patients receiving systemic
therapy.12–14 18FDG–PET may also be helpful in detecting resis-
tance to tyrosine kinase inhibitors.14–17 Although 18FDG–PET
provides hopes for better tumor characterization, preoperative
staging, and detection of treatment response, its usage is uncom-
mon in many countries,18 and its role in evaluation of response
to treatment is under continuous investigations. Therefore, strong
evidence is required on the routine use of this technique in clinical
decision making. Meta–analyses provide practical evidence for re-
searchers regarding advantages and side effects of an intervention
to help them decide if to proceed with clinical trials or not. Al-
though there are many studies in order to identify clinical beneﬁts
of 18F-FDG–PET in prediction of therapeutic response of GIST
patients, but no meta-analyses have been conducted for this pur-
pose. Therefore, the present systematic review and meta-analysis
assessed the value of 18F-FDG–PET on prediction of therapeutic
response of GIST patients to systemic treatments.
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Methods
Search strategy. The present study was performed according
to the meta-analysis of Observational Studies in Epidemiology
(MOOSE) statement providing a detailed guideline of preferred
reporting style for systematic reviews and meta-analyses.19 Rele-
vant articles were enrolled over a literature search of online data-
bases including Medline (via PubMed), EMBASE (via OvidSP),
SCOPUS, Cochrane Library, and Google Scholar databases from
January 2000 to June 2015. There is no language limitation. The
initial search was broad and included and based on following
phrases: “Gastrointestinal Stromal Tumors” or “GIST”, and
“Positron-Emission Tomography” or “PET”. In addition, a hand
search was performed in the bibliography of eligible and reviews
articles. In addition, it was attempted to contact with authors of
all studies that met entrance criteria and requested them for unpub-
lished data and abstracts to gather grey literature. A hand search
was also conducted in Google search engine and Google scholar
to include non-indexed reports. Moreover, hand-searching of
journals was also carried out.
Study Selection and Deﬁnitions. Two reviewers (M.Y,
S.K) independently summarized all potentially relevant studies,
and disagreement was resolved by discussion. We included all
studies that investigated the role of 18F-FDG–PET and positron
emission tomography – computed tomography (PET/CT) in
predicting treatment response in eligible GIST patients from all
age groups. Only prospective, blinded, and original research was
enrolled. Eligible studies fulﬁlled all of the following criteria: (i)
histological diagnosis of GIST; (ii) sample size of at least eight pa-
tients with GIST; (iii) 18F-FDG–PET and PET/CT performed in
patients with GIST in order to predict treatment response to che-
motherapy; and (iv) performing PET before and after treatment.
Including patients with other cancers, lack of blinding of observer,
and poor quality studies based on a modiﬁed Quality Assessment
of Diagnostic Accuracy Studies (QUADAS2) tool20 was exclusion
crteria. In addition, for guaranteed of power of included study,
studies with less than eight patients (in ﬁnal follow-up) were
excluded.
Data extraction and management. Two reviewers (M.
Y, S.K) independently summarized informations from studies with
a standardized data abstraction form. Study design, patient charac-
teristics, GIST diagnosis criteria, PET device, PET criteria for
treatment response, CT criteria for treatment response, time inter-
val of PET performance after intervention, and sampling method
were included in the abstraction forms. In cases of missing or in-
sufﬁcient data, and if necessary, authors were contacted for clariﬁ-
cation of study sample.
If a study included several types of cancers, only GIST patients’
data were used.
Quality assessment. Quality of the included studies was
assessed based on 15-item modiﬁed Quality Assessment of Diag-
nostic Accuracy Studies (QUADAS2). Two reviewers (M.Y, S.
K) independently assessed each potentially eligible study and
assigned them as a quality rating of “good,” “fair,” or “poor”.
Quality assessment was conducted based on following criteria:
study design and presence of bias including selection, perfor-
mance, recording, and reporting bias. Studies with high risk of bias
were deﬁned as poor quality, presence of moderate risk (did not
affect the results) as fair quality, and those with minimal risk as
good quality. In this regards, inter-rater reliability was acceptably
high (91%). Disagreements were settled with consensus decision.
Data synthesis and statistical analysis. Statistical
analysis was performed using STATA software version 12.0
(StataCorp, College Station, TX, USA). Data were presented as
true positive (true prediction of response to treatment), true nega-
tive (true prediction of treatment failure), false positive (false pre-
diction of response to treatment), and false negative (false
prediction of treatment failure) values. In cases which ﬁndings of
the study were reported as the number of lesions, authors were
contacted to ﬁnd the total sample size (number of patients). If they
did not respond, estimation methods were used to calculate the
true positive, true negative, false positive, and false negative
values according to the web-based calculator. If the information
was reported as graphs, data were extracted from them as recom-
mended by Sistrom and Mergo.21
A mixed-effects binary regression model was used. This
method is a type of random effect model when the heterogeneity
source was not clear. Statistical heterogeneity was deﬁned using
the I2 and χ2 tests (P< 0.10 was representative the signiﬁcant sta-
tistical heterogeneity).22 Sensitivity and subgroup analyses were
performed to assess the expected or measured heterogeneity.
For this purpose, a bivariate meta-regression model was ﬁtted.
All possible causes of heterogeneity including the sample size,
PET device (PET or PET/CT), PET criteria, drug evaluated, and
PET performance after intervention were included as covariates
in the meta-regression model. Publication bias was assessed by
funnel plot and associated regression test of asymmetry, intro-
duced by Deeks et al.23 Finally, the pooled sensitivity and speci-
ﬁcity were calculated with 95% conﬁdence intervals (CIs).
Predictive odds ratio (POR) and receiver operative curves (ROCs)
were also obtained.
Result
• Literature search
In 1973, non-duplicate articles were identiﬁed by using search
strategies from which 63 potentially relevant papers were
screened. Finally, 32 study were eligible, and 21 full-text articles
included in meta-analysis and studied in detail13,15,24–42 (Table 1,
Fig. 1). These studies contained 642 patients, with average age of
56.2 years and 402 (62.6%) male individuals. Twelve (57.1%)
study used 18FDG–PET and 9 (42.9%) used PET/CT for assess-
ment of treatment response. In average, ﬁrst PET assessment was
performed 27.2 days after chemotherapy (range: 0–180 days)
(Table 1).
• Heterogeneity and publication bias
A bivariate mixed-effects binary regression model was used for
performing analyses, because a signiﬁcant statistical heterogeneity
was found in calculation pooled sensitivity (Q = 52.59;
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I2 = 61.97%; P= 0.001), speciﬁcity (Q= 65.93; I2 = 69.66%;
P= 0.001), POR (Q = 26112; I2 = 100.0%; P< 0.001). No publica-
tion bias was observed among included studies (P= 0.19).
• Meta-analysis
The analysis showed the pooled sensitivity and speciﬁcity of
18FDG–PET for prediction of response to treatment were 0.90
(95% CI: 0.85–0.94; I2 = 52.59, P = 0.001) and 0.62 (95% CI:
0.49–0.75; I2 = 69.7, P = 0.001), respectively (Fig. 2). The
pooled POR for \18FDG–PET was 14.99 (95% CI, 6.42–
34.99; I2 = 100.0, P< 0.001) (Fig. 3). The summary receiver
operating characteristic (SROC) curves for PET is presented
in Figure 4. The area under curve was 0.89 (95% CI:
0.86–0.92).
• Subgroup analysis
The subgroup analysis showed sample size, type of PET device
for assessing response to treatment, and PET criteria were the main
possible sources of heterogeneity. The meta-regression showed
that the sensitivity (sensitivity = 0.93; 95% CI: 0.89–0.97) of
18FDG–PET was higher if the sample size of study was equal or
more than 30 cases. In addition, using PET/CT was associated
with higher pooled sensitivity (sensitivity = 0.92; 95% CI: 0.89–
0.97). Interestingly, using European Organization for Research
and Treatment of Cancer (EORTC) or PET Response Criteria In
Solid Tumors (PERCIST) criteria is associated with lower sensi-
tivity (sensitivity = 0.89; 95% CI: 0.84–0.94) compared with
self-design criteria (sensitivity = 0.93; 95% CI: 0.87–1.0)
(Table 2).
Discussion
The present meta-analysis declared the value of 18FDG–PET for
predicting treatment response in GIST patients. Overall, it seems
that the value of 18FDG–PET is higher for detection of treatment
failure (higher sensitivity) than prediction of good response (low
speciﬁcity) even after adjusting for possible sources of heteroge-
neity (the lowest PET subgroup sensitivity was 0.85). Using
Table 1 Studies of predictiv value of PET in response to treatment
Authors Year
Sample
size Age† Male (%) PET device
Timing
of PET‡ PET criteria CT criteria Drug
Van Oosterom et al.24 2001 40 53 62 PET 30 EORTC RECIST Imatinib
Stroobants et al.25 2003 21 55 57 PET 8 EORTC RECIST Imatinib
Gayed et al.26 2004 54 56 57 PET 60 EORTC ≥5% decrease
in tumor size
Imatinib
Jager et al.27 2004 16 60 71 PET 7 20%-40%
reduction of SUV
RECIST Imatinib
Choi et al.28 2004 29 55 50 PET 2 EORTC RECIST Imatinib
Antoch et al.15 2004 20 60 55 PET/CT 30 EORTC RECIST Imatinib
Goldstein et al.29 2005 18 NR NR PET 2 EORTC RECIST Imatinib
Goerres et al.30 2005 24 52 56 PET/CT 3 EORTC RECIST Imatinib
Holdsworth et al.31 2007 98 55 63 PET 0 EORTC SWOG Imatinib
Choi et al.32 2007 40 NR 47 PET 2 70% reduction
of SUV
RECIST Imatinib
Prior et al.33 2009 22 53 69 PET 1 EORTC RECIST Sunitinib
McAuliffe et al.34 2009 16 59 58 PET 1 40% reduction
of SUV
≥10% decrease in
tumor blood ﬂow
Imatinib
Demetri et al.35 2009 60 55 66 PET 7 EORTC RECIST Sunitinib
Maurel et al.36 2010 24 57 92 PET/CT 14 EORTC RECIST Imatinib +
doxorubicin
Fuster et al.37 2010 21 57 NR PET/CT 60 EORTC RECIST Imatinib +
doxorubicin
Bertagna et al.38 2010 19 61 68 PET/CT 60 SUV greater
than 3
RECIST Imatinib
Van den Abbeele et al.39 2012 40 55 50 PET 7 EORTC RECIST Imatinib
Herrmann et al.40 2012 38 53 49 PET/CT 30 EORTC RECIST Ifosfamide +
doxorubicin
Zukotynski et al.41 2014 17 65 23 PET/CT 30 EORTC RECIST Imatinib
Camacho et al.13 2014 9 58 44 PET/CT 180 PERCIST RECIST Yttrium
Chacón et al.42 2015 15 49 50 PET/CT 37 EORTC RECIST Imatinib
†, Number is presented as mean (years)
‡, Time interval of PET performance after intervention (day)
CT: Computed tomography; EORTC: European organization for research and treatment of cancer; NR: Not reported; PET: Positron emission tomogra-
phy; PERCIST: PET response criteria in solid tumors; RECIST: Response evaluation criteria in solid tumors; SUV: Standard uptake value; SWOG: South-
west oncology group.
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Figure 1 Flow chart of the study. Diagram represents the review process and selection of included studies
Figure 2 Forest plot for sensitivity and speciﬁcity of PET for predicting treatment response.
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PET/CT was associated with higher sensitivity in prediction of
treatment response. It might be due to fusion of transaxial, sagital,
and coronal images obtained by PET and CT components of the
study, which provide simultaneous functional and anatomical
information, leading to more accurate diagnosis.
A systematic review performed by Treglia et al., who reviewed 19
studies, demonstrated PET has a signiﬁcant value in assessing treat-
ment response to treatment inGIST. They stated thismodality allows
an early assessment of treatment response and is a strong predictor of
clinical outcome.43 In another review, Donswijk et al. showed PET
(/CT) is a valuable tool to monitor response in patients with GIST
treated by tyrosine kinase inhibitors.44 Also, Sheikhbahaei et al. after
reviewing 14 studies demonstrated that FDG–PET/CT provides
advantages in the initial tumor staging, tumor grading, therapy
assessment, and recurrence detection in these tumors.45 These
ﬁndings were in concordance with the present meta-analysis.
Based on our knowledge, the present study is the ﬁrst quantita-
tive, meta-analytic approach to review all available evidence re-
garding the predictive value of 18FDG–PET on treatment
response in GIST tumor. We performed a wide search in several
databases to include the extreme number of relevant studies. This
search strategy led to ﬁnd 21 relevant articles. However, the pres-
ent meta-analysis had a number of potential limitations. First, the
predictive value of 18FDG–PET in GIST patient was reported
without adjusting for potential confounders such as grading and
staging of patients. Moreover, the heterogeneity between studies
was another issue. Therefore, it was decided to perform a bivariate
mixed random effects model provided more conservative results.
Figure 3 Forest plot for predictive odds ratio of PET for predicting treatment response.
Figure 4 Summary receiver operative curves (SROC) for PET. AUC,
Area under the curve. ( ) Observed Data, ( ) Summary Operating Point
SENS = 0.90 [0.850.94]; SPEC = 0.62 [0.490.75], ( ) SROC Curve;
AUC = 0.89 [0.860.92], ( ) 95% Conﬁdence Contour, ( ) 95%
Prediction Contour.
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Conclusion
The present meta-analysis showed 18FDG–PET has a signiﬁcant
value in assessing treatment response in GIST patients. Accuracy
of 18FDG–PET is higher in detection of treatment failure than pre-
diction of good response to treatment even after adjusting for pos-
sible sources of heterogeneity. Using 18FDG–PET/CT was
associated with higher sensitivity in prediction of treatment
response.
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